Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celgene : Says EC Approves two Triplet Regimens for Multiple Myeloma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 09:31am EDT

By Michael Dabaie

Celgene Corp. (CELG) said the European Commission has approved two new triplet regimens based on Celgene's Revlimid and Imnovid.

Revlimid in combination with bortezomib and dexamethasone is now indicated for the treatment of adult patients with previously untreated multiple myeloma who aren't eligible for transplant.

Imnovid, in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide, the company said.

The triplet regimens aren't approved for use in the U.S., Celgene said.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
08/19Who is next in big pharma's merger spree?
RE
08/19CELGENE CORPORATION : - U.S. FDA Approves INREBIC as First New Treatment in Near..
AQ
08/16CELGENE : FDA Grants Approval to Celgene's Impact for Bone Marrow Disorder Treat..
DJ
08/16CELGENE : U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Near..
BU
07/30CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/30CELGENE : Second-Quarter Revenue at Celgene Surpasses Wall Street Targets
DJ
07/30CELGENE : 2Q Earnings Snapshot
AQ
07/30CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
AQ
07/30CELGENE : Reports Second Quarter 2019 Operating and Financial Results
BU
07/29Pfizer to spinoff, merge off-patent drugs unit with Mylan
RE
More news
Financials (USD)
Sales 2019 17 366 M
EBIT 2019 10 140 M
Net income 2019 6 470 M
Debt 2019 1 302 M
Yield 2019 -
P/E ratio 2019 10,9x
P/E ratio 2020 9,15x
EV / Sales2019 3,96x
EV / Sales2020 3,24x
Capitalization 67 515 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 100,14  $
Last Close Price 95,26  $
Spread / Highest target 26,0%
Spread / Average Target 5,13%
Spread / Lowest Target -11,8%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION48.63%67 486
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341
PFIZER-20.62%194 582